Adjuvant chemotherapy plus radiation versus chemotherapy alone in stage III-IVA endometrial cancer: a phase II randomized controlled trial
Phase 2
- Conditions
- Evaluate pelvic recurrent rate and survival outcome in stage III-IVA endometrial cancer who receive adjuvant chemotherapy plus radiation versus chemotherapy aloneendometrial cancerradiationadjuvant treatment
- Registration Number
- TCTR20240725003
- Lead Sponsor
- Mahidol University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- Female
- Target Recruitment
- 75
Inclusion Criteria
1. Participants must be 18 years of age or older.
2. Participants must have been diagnosed with stage III-IVA endometrial cancer through surgical staging at Siriraj Hospital.
3. Participants must not have any suspicious pathological lymph nodes on radiographic imaging (CT scan, MRI, or PET scan) following chemotherapy.
Exclusion Criteria
1. Participants who have progression of disease of during or after receiving chemotherapy.
2. Participants who develop secondary cancer while participating in the research study.
3. Participants who have previously received radiation therapy to the pelvic area.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pelvic recurrence 24 months after intervention physical examination, CT scan
- Secondary Outcome Measures
Name Time Method extra pelvic recurrence 24 months after intervention physical examination, CT scan